TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07540897: A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Sponsor: Alkermes, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$3,347,224

Rescue Site Savings

+$2,215,768

Unlock Full NCT07540897 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07540897 Rescue Dossier →